Form 4: Acadia Pharmaceuticals Director Adora Ndu Reports Stock Transactions
SEC Form 4 Filing
Director Adora Ndu reports the vesting and disposal of restricted stock units in Acadia Pharmaceuticals.
Summary
- On October 12, 2024, Adora Ndu, a director of Acadia Pharmaceuticals, reported transactions involving restricted stock units.
- Ndu acquired 4,381 shares of common stock through the vesting of restricted stock units.
- Simultaneously, Ndu disposed of 4,381 shares.
- Following these transactions, Ndu directly owns 15,414 shares of Acadia Pharmaceuticals common stock.
Sentiment
Score: 5
Explanation: The document is a neutral regulatory filing, reporting stock transactions. It doesn't inherently convey positive or negative sentiment.
Industry Context
This is a routine disclosure of stock transactions by a company insider, which is common practice and required by the SEC to ensure transparency and prevent insider trading.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine insider transaction.
Key Dates
| Date | Description |
|---|---|
| 10/12/2023 | First vesting date of restricted stock units in two equal annual installments |
| 10/12/2024 | Date of transaction: vesting and disposal of restricted stock units; second vesting date of restricted stock units in two equal annual installments |
| 10/14/2024 | Date of report submission |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.